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Background/aim: Huntington disease (HD) is a progressive adult-onset neurodegenerative disorder presenting an autosomal dominant
inheritance. Since there is no information on the prevalence of HD in northwestern Iran, the aim of the present study was to determine
the prevalence of HD and the number of CAG trinucleotide repeats in the population of northwestern Iran.
Materials and methods: Genomic DNA was extracted from whole blood by the salting-out method. DNA samples were analyzed to
determine the number of CAG trinucleotide repeats of the HD gene. An abnormally large number of CAG repeats, which is a diagnostic
factor for the disease, was detected by polymerase chain reaction and agarose gel electrophoresis.
Results: Out of 40 cases, we identified 14 nonkindred individuals with one expanded CAG allele at the IT15 gene. The frequency of the
HD mutation in our group of patients was 35%. Expanded alleles varied from 36 to 70 CAG repeats, and normal alleles in HD patients
varied from 20 to 26 CAG units.
Conclusion: We found a significant correlation between age at onset of the disease and length of the expanded CAG tract: the lower the
age, the longer the trinucleotide repeats length.
Key words: CAG trinucleotide repeats, Huntington disease, IT15

1. Introduction
Huntington disease (HD) is a progressive hereditary
neurodegenerative disorder that affects the central nervous
system (1). HD is an autosomal dominant disease due to the
expansion of CAG trinucleotide repeats in the HD gene (IT15)
located at 4p16.3 and encoding a protein called huntingtin
(2,3). The number of the repeats is normally between 6 and
34 in healthy individuals, while it is expanded to more than
40 repeats in people with HD (4,5). The expansion of CAG
repeats results in an expanded polyglutamine sequence in
the resulting protein, which leads to abnormal interactions
of the huntingtin protein with other nuclear proteins.
These abnormal aggregations in brain cells cause cellular
death (6). In HD, the basal ganglia and the cerebral cortex,
which control concentration, memory, and coordination of
movements, are affected more than the other regions (7).
The exact function of the huntingtin protein is unclear, but
it is known to be associated with microtubules and synaptic
vesicles, suggesting a role in the transport of substances or
cell components along the microtubules to the synapses (the
structures that facilitate communication between neurons)
(8,9). In addition, there is some evidence that apoptosis
plays a role in HD (10,11).
* Correspondence: mahmoud.khaniani@gmail.com
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One of the major characteristics of HD is uncontrollable
muscular movements, or chorea, and hence the name
Huntington’s chorea of the disease (12). The other
characteristics of the disease are short-term memory
abnormalities, poor concentration, speaking problems,
and cognitive (perception, awareness, thinking, and
judgment) and psychological issues, such as mood swings,
clumsiness, changes in gait, fidgety movements, irritability,
depression, and uncharacteristic aggressive behavior,
which can be quite different even among members of a
single family (13,14). In addition, the rare phenomenon of
“anticipation” has been observed in HD, which means that
the age of onset and the severity of symptoms will decrease
and increase, respectively, in subsequent generations
(6,15). The anticipation phenomenon is believed to be
the result of instability of the trinucleotide repeats during
meiosis (16).
Although the symptoms are usually detectable in the
fourth decade of life, the age of onset is highly variable, in
that symptoms are observed at early ages or in people as
old as 90 years (17). The average life expectancy is almost
15 years after the onset of symptoms (18,19). There is
no complete therapy for HD, but in the case of an early
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diagnosis, one might take advantage of therapeutics that
alleviate the symptoms and control the progression of the
disease. Early symptoms can be managed and alleviated
with drugs, such as depleting agents and other forms of
therapy, to improve the quality of life. In addition, chorea
can be treated with dopamine receptor blocking drugs (20).
Based on comprehensive studies in different
populations, the prevalence of the disease is estimated to be
5 in 100,000 (18,19,21,22). However, there is no statistical
information on its prevalence in northwestern Iran.
Therefore, the aim of the present study was to estimate the
prevalence of the disease in the area and to determine the
number of CAG trinucleotide repeats in HD alleles.
2. Materials and methods
2.1. Subjects
A group of 42 clinically affected and unrelated individuals,
including 18 females and 24 males, were recruited. Blood
samples were obtained from individuals for DNA testing
after obtaining written informed consent. According to
their clinical details, which were based on extensive records
documenting their neurological examination, all patients
showed typical HD symptoms such as chorea, movement
impairment, cognitive disorders, and personality changes.
The probability of developing other neurodegenerative
diseases was ruled out by pedigree analysis and clinical
tests in all cases.
A group of 21 unaffected individuals was recruited as
controls that were similar to the clinical cases age- and sexwise. The patients were referred to the outpatient clinic of
Tabriz University of Medical Sciences between June 2012
and April 2015, and a 5-mL blood sample was drawn
from all the subjects. This study was approved by the
ethical committee of Tabriz University of Medical Sciences
(Tabriz, Iran).
2.2. DNA extraction
The salting-out method was used to extract genomic DNA
from the peripheral blood of subjects and controls. To
determine the DNA concentration and quality, extracted
DNAs were analyzed by NanoDrop.
2.3. Polymerase chain reaction (PCR)
The basis of screening tests is to measure the sizes of
the CAG repeats in each individual by performing PCR
(23). The PCR amplification method was conducted for
the IT15 gene in the Bio-Rad T100 thermal cycler. PCR
amplification of the CAG repeat in the IT15 gene was
performed with primers HD1 (5′-ATGAAGGCCTCCG
AGTCCCTCAAGTCCTCC-3′, Tm: 75 °C) and HD3
(5′-GGCGGTGGCGGCTGTT GCTGCTGCTGC-3′, Tm:
79 °C) (2,23,24). The primer pair was designed by using
a software tool from the NCBI database, available in the
primer BLAST tool section.
To perform PCR, 7.5 µL of mix red from CinnaGen
Company, 1 µL of forward primer, 1 µL of reverse primer,

5 µL of Q-Solution, 1.5 µL of H2O, and 1 µL of DNA were
added to microtubes for a final volume of 17 µL.
The thermal profile for PCR was as follows: 98 °C for
15 min; 35 cycles of 98 °C for 1 min, 70 °C for 1 min, and
72 °C for 2 min; and 72 °C for 10 min as final extension.
2.4. Electrophoresis
The stained PCR products were used for electrophoresis
on a 3% agarose gel containing Safe Stain. The sizes of
visualized bands of the IT15 gene in healthy controls
and HD patients were 100–120 and 200–250 base
pairs, respectively. The number of CAG trinucleotide
repeats in respective chromosomes of HD patients was
estimated using the DNA fragment size determined by
electrophoresis (Figure).
3. Results
The number of CAG repeats within the gene determines
whether an individual has normal (5–26 repeats), normal
with paternal meiotic instability (27–35 repeats), alleles
with reduced penetrance (36–39 repeats), or HD-affected
(>40 repeats) alleles. However, normal results do not
guarantee a definite exclusion of developing HD, as there
is still a probability that other very rare mutations may
produce the HD phenotype.
In this study, 42 patients were examined and 15
affected individuals were diagnosed with heterozygous
expanded CAG trinucleotide repeats in the IT15 gene.
The number of trinucleotide repeats within a normal allele
is approximately 20 to 26, whereas in mutant alleles it is
approximately 40 to 70 (Table).

Figure. Analysis of PCR products containing the expanded CAG
repeat at the IT15 gene. PCR products were analyzed on 3%
agarose gel. Allele sizes were determined by comparison with a
sequencing ladder (50 bp). 1- Ladder; 2- no DNA; 3- positive
control; 4- patient; and 5- normal subject.
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Table. Molecular basis of Huntington patients.
Patient

Sex

Age at onset

CN of normal allele

CN of expanded allele

Transmission

HD6

F

35

23

70

Paternal

HD9

M

41

26

50

Paternal

HD14

M

45

23

60

Paternal

HD17

F

47

23

50

Paternal

HD19

F

49

23

60

Paternal

HD21

M

51

23

50

Isolated

HD23

F

51

26

50

Maternal

HD26

F

53

23

50

Paternal

HD28

F

55

23

50

Maternal

HD32

M

57

26

45

Paternal

HD36

F

59

23

45

Paternal

HD37

M

60

20

50

Paternal

HD39

M

66

20

45

Paternal

HD42

M

67

23

50

Isolated

HD44

M

70

20

40

Maternal

F: Female, M: male, CV: copy number.

The youngest affected individual was a 35-year-old
patient with the most number of CAG trinucleotide repeats
(70 repeats), which resulted in more severe symptoms, and
the oldest affected individual was a 70-year-old patient
with the least number of CAG trinucleotide repeats (40
repeats) within one of the mutant HD alleles.
The number of CAG trinucleotide repeats in affected
individuals who were between 40 and 60 years old when
symptoms emerged was 45–60. Therefore, the higher
the number of repeats, the lower the age at the onset of
symptoms and the more severe the symptoms.
Autosomal dominant inheritance could be documented
in all but 2 patients who had no family history of the
disease. The transmission of the disease was paternal in 10
and maternal in 3 cases. There was no significant difference
in the size of expanded CAG repeats between patients with
paternal inheritance.
4. Discussion
In recent decades, a mechanism of mutation has been
reported in humans, called dynamic mutation, which is
the result of the expansion of trinucleotide repeats (25).
HD, along with other neurodegenerative diseases such as
Kennedy disease and spinocerebellar ataxias (1–3,6,7),
is the result of CAG trinucleotide expansion in the
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corresponding gene, which results in polyglutamine tracts
in the resulting protein (26,27).
In the present study, the expansion of CAG
trinucleotides has been detected in 36% (15/42) of HDsuspected individuals. This is the first molecular study of
the disease in northwestern Iran. The results indicate a
significant relationship between the length of the repeats
and the age of onset. The length of CAG repeats in healthy
individuals and the normal allele of the affected ones was
20–26, while most of the patients between the ages of 41
and 60 had nearly 50 repeats in at least one allele. The
average lengths of CAG trinucleotide repeats in normal
and HD alleles observed in this study are comparable
to the findings of other studies (24,28). It should be
mentioned that, using gel electrophoresis, it is only
possible to determine the approximate number of repeats;
to determine the exact number, sequencing of the exons of
the gene is essential.
There is some evidence that shows that de novo
mutations can be the cause of sporadic HD (24,28). In
the population we studied, there were 2 (13%) individuals
without a family history of HD.
The results showed that the expansion of CAG
in consecutive generations occurs only when the
mutant allele is inherited paternally (24,28). Therefore,
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meiotic instability of the HD allele takes place during
spermatogenesis (29). In the present study, by analyzing
the pedigrees of patients, it was observed that 66% (10/15)
of the individuals inherited the mutant allele paternally and
20% (3/15) inherited it maternally. In addition, in paternal
inheritance, the patients had more severe symptoms at
earlier ages as compared to their fathers.
Regarding HD diagnosis, it is important to not
misdiagnose the disease as other similar diseases, such
as chorea gravidarum, hyperthyroid chorea, and vascular
hemichorea, all of which have chorea-like symptoms.
Unlike HD, these diseases are not hereditary and do not
involve permanent speech and cognitive disorders (25).
In recent years, several diseases with symptoms
similar to HD have been identified. These are referred to
as HD-like (HDL) diseases. HD includes approximately
90% of hereditary chorea cases, while HDL includes only

1% (6,15). Phenotypic overlap between HD and HDL is
a major challenge for HD diagnosis. There are several
mutations in various genes that bring about HDL diseases,
such as HDL1, HDL2, and HDL4, all of which have an
autosomal dominant inheritance. HDL3 is probably
inherited in an autosomal recessive pattern, which means
that both copies of the gene in each cell have mutations
(8,9,18).
In the population that we studied, those who
did not have HD mutations, i.e. CAG trinucleotide
expansion, probably had HDL mutations. Therefore, it is
recommended that along with HD mutations, researchers
evaluate common HDL mutations.
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